pipette
ESEspañol

Once-Weekly Ribupatide for Weight Loss in Adults in China With Overweight or Obesity: The GEMINI-1 Randomized Clinical Trial

Lin Zhao, Ying Chen, Zhifeng Cheng, Dan Zhu, Qifu Li, Hanqing Cai, Yuan Hui, Qi Wang, Junfeng Han, Zongyou Cheng, Guiping Li, Shumei Zhong, Jinyang Wang, Lianwei Wang, Chao Meng, Shu Li, Hongye Su, Yi Xu, MEIFANG ZENG, Yue ZUO, Lei Zhang, Wenhua Wei, L Wang, YIKE WANG, Minzhi Lv, Hong Chen, Xiaoying Li

Peer-reviewed journalReal-world use

In the authors' words

This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.

Main result
CONCLUSIONS AND RELEVANCE Among adults in China with overweight or obesity without diabetes, once-weekly subcutaneous ribupatide resulted in significantly greater weight loss at 48 weeks.

Appeared: Tuesday, November 17. JAMA. Peer-reviewed journal.

DOI: 10.1001/jama.2026.24796